gastrin

Gastrin/CCK antagonist 1 is a potent gastrin/CCK antagonist for the study of metabolic system-related diseases.

Gastrin-Releasing Peptide, human(TFA) is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Mini Gastrin I, human acetate is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

Gastrin I, rat is a peptide hormone that effectively stimulates gastric acid secretion.

[Leu15]-Gastrin I, human is a variant of Gastrin I, where the 15th amino acid residue is substituted with leucine (Leu). [Leu15]-Gastrin I (human) regulates the binding of cholecystokinin to the mucosal membrane.

Gastrin I (1-14), human TFA, is the 1-14 fragment of the human gastrin I peptide.

Gastrin I (1-14), human, is the 1-14 peptide fragment of human gastrin I, an endogenous gastrointestinal peptide hormone, and is the primary hormonal regulator of gastric acid secretion.

Mini Gastrin I, human, is a truncated form of the human gastrin peptide, encompassing amino acids 5-17 of the original sequence.

Gastrin I, human (Gastrin I (human)) is an endogenous peptide produced in the stomach that increases pepsinogen and acid secretion via the CCK2 receptor in the rat.

Tetragastrin is the C-terminal tetrapeptide of gastrin. It has the same physiological and pharmacological activity as gastrin.

Gastrin-Releasing Peptide, human is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Gastrin I (human) acetate (Gastrin-17 acetate) is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

Gastrin(1-17)-BSA is a hapten-carrier protein conjugate formed by coupling Gastrin(1-17) to bovine serum albumin (BSA). As a hapten, Gastrin(1-17) alone cannot induce an immune response and must be conjugated to a large molecular protein to become a complete antigen with immunogenicity. The peptide partial sequence is Pyr-GPWLEEEEEAYGWMDF-NH₂. Gastrin(1-17)-BSA may be supplied as a lyophilized powder or as a solution. The solution is prepared in 0.01 M TBS (pH 7.4) buffer at a typical concentration of 1 mg/mL.

Thiazolidinone-Derivatives-1 inhibits the secretion of gastric acid and can be used in research on the treatment of gastric and duodenal ulcers.

GRP (porcine) acetate is the gastrin-releasing peptide extracted from porcine pancreata. GRP (porcine) acetate may have a role in the parasympathetic regulation of endocrine and exocrine secretion from the pig pancreas.

Sograzepide (Netazepide) is an orally active, selective and highly potent gastrin/CCK-B antagonist that inhibits gastrin/CCK-A activity and pappalysin 2 expression in type 1 gastric neuroendocrine tumors, and can induce regression of type 1 gastric neuroendocrine tumors.

L-365260 is an orally available, selective and potent nonpeptide gastrin and cerebral cholecystokinin receptor (CCK-B) antagonist.L-365260 inhibits CCK-8S-induced increase in [Ca2+]i, blocks stress-induced hypersensitivity in viscera, and blocks the anti-exploratory effect of CCK-4.L-365260 has been used in the study of neurological Ojibwa and endocrine diseases.

Linaprazan glurate inhibits both exogenously and endogenously stimulated gastric acid secretion and can be utilized in studies on gastrointestinal inflammatory diseases and peptic ulcer diseases.

Benzotript is an gastrin-receptor antagonist, with anti-gastrinic.

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin/CCK-B (IC50: 0.43 nM). It also inhibits gastrin/CCK-A activity (IC50: 1.82 μM).

RC-3095 TFA (RC-3095 (TFA)) is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.

Biotin-Gastrin Releasing Peptide, human, is a biotinylated derivative of gastrin-releasing peptide (GRP), a neuropeptide known for its growth-stimulatory and tumorigenic properties [1].

Biotin-Gastrin Releasing Peptide, human TFA, is a biotinylated form of the gastrin-releasing peptide (GRP). GRP is a neuropeptide known for its growth-stimulating and tumorigenic properties.

Biotin-Gastrin-1, human (1-17) is a bioactive peptide.